Last reviewed · How we verify
NCT03595969
Association Between Mitochondrial DNA Content and Risk of Acute Leukemia
trial testing Relative copy number of mitochondrial DNA in Lymphoblastic Leukemia in Children in 300 participants. Completed in 1 October 2019.
1 October 2019
Quick facts
| Lead sponsor | Air Force Military Medical University, China |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 1 November 2018 |
| Primary completion | 1 October 2019 |
| Estimated completion | 1 October 2019 |
| Sites | 1 location across China |
Drugs / interventions tested
- Relative copy number of mitochondrial DNA
Conditions studied
- Lymphoblastic Leukemia in Children — all drugs for Lymphoblastic Leukemia in Children →
Sponsor
Air Force Military Medical University, China
Who can join
Under 16, any sex, with Lymphoblastic Leukemia in Children. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Compelling epidemiological evidence indicates that alterations of mitochondrial DNA, including mutations and abnormal content of mitochondrial DNA (mtDNA), are associated with the initiation and development of acute lymphoblastic leukemia (ALL).The aim of this study was to explore association between mtDNA content in peripheral blood cells could be used as a risk predictor for ALL.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03595969
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lymphoblastic Leukemia in Children
Currently open trials in the same condition.
- NCT06099366 — Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children · Phase 2 · recruiting
- NCT05043571 — CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia · Phase 1 · recruiting
- NCT05038696 — ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia. · Phase 1 · recruiting
Other Air Force Military Medical University, China trials
Trials by the same sponsor.
- NCT07535138 — Efficacy and Safety of CD19 CAR-γδ T Cells in the Treatment of Relapsed/Refractory Autoimmune Nephropathy · EARLY_PHASE1 · not yet recruiting
- NCT07454408 — Evaluation of the Outcome of Fecal Microbiota Transplantation · Phase 1, PHASE2 · not yet recruiting
- NCT07329660 — Crystalloid vs Colloid for Hemodynamics During Anesthesia Induction in TAVR Patients · NA · not yet recruiting
- NCT07365345 — Frequency of Electrical Acupoint Stimulation on Hypotension in TAVR Patients · NA · recruiting
- NCT07338448 — Electrical Acupoint Stimulation on Gastric Reflux During I-gel Ventilation · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03595969 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Air Force Military Medical University, China
- Last refreshed: 10 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03595969.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing